NEW YORK ( TheStreet) -- Depomed ( DEPO) was the lone star of Friday's after-hours session as shares of the Menlo Park, Calif.-based drug developer surged following favorable regulatory news.

After the closing bell, Depomed said it's received marketing approval from the Food and Drug Administration of its Gralise one-daily tablets for the treatment of post-herpetic neuralgia, also known as shingles. Gralise also received orphan drug status, which gives it seven years of marketing exclusivity.



The stock was last quoted at $7.37, up 18.1%, on volume of nearly 85,000, according to Nasdaq.com. Based on a regular session close at $6.24, the share had already more than doubled over the past 52 weeks.

Depomed has licensed Gralise to Abbott Products, a unit of Abbott Laboratories ( ABT), and the FDA approval triggers a $48 million milestone payment to Depomed.

The licensing deal with Abbott also includes sales milestone payments of up to $300 million, and calls for Depomed to receive royalties of 14% to 20% on sales of Gralise.

Depomed is slated to report its fourth-quarter results on Feb. 28. The current average estimate of analysts polled by Thomson Reuters is for a profit of 39 cents a share in the December period on revenue of $20.8 million.

-- Written by Michael Baron in New York.

>To contact the writer of this article, click here: Michael Baron.

>To submit a news tip, send an email to: tips@thestreet.com

If you liked this article you might like

Opioid Litigants Get Boost From Senate Report

Opioid Litigants Get Boost From Senate Report

Skyworks Solutions Is 1 of 5 Big Stocks Ready to Abruptly Change Direction

Skyworks Solutions Is 1 of 5 Big Stocks Ready to Abruptly Change Direction

These Are the Biggest Winners and Losers in Activist Investing This Year

These Are the Biggest Winners and Losers in Activist Investing This Year

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

Opioid Makers Buffeted by Trump's Declaration of Addiction Crisis

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study

Biotech Movers: FibroGen Leaps on Results for Pulmonary Fibrosis Study